Maria Silk

1.8k total citations · 3 hit papers
18 papers, 884 citations indexed

About

Maria Silk is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Dermatology. According to data from OpenAlex, Maria Silk has authored 18 papers receiving a total of 884 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Rheumatology, 7 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Dermatology. Recurrent topics in Maria Silk's work include Systemic Lupus Erythematosus Research (12 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Dermatology and Skin Diseases (4 papers). Maria Silk is often cited by papers focused on Systemic Lupus Erythematosus Research (12 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Dermatology and Skin Diseases (4 papers). Maria Silk collaborates with scholars based in United States, Germany and Japan. Maria Silk's co-authors include Yoshiya Tanaka, Thomas Dörner, Michelle Petri, Jonathan Janes, Daniel J. Wallace, Marta Mosca, Kenneth Kalunian, Stephanie de Bono, Richard Furie and Ian N Bruce and has published in prestigious journals such as The Lancet, Neurology and Annals of the Rheumatic Diseases.

In The Last Decade

Maria Silk

15 papers receiving 876 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

2018 356 citations Daniel J. Wallace, Richard Furie et al. The Lancet profile →
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

2023 89 citations Michelle Petri, Ian N Bruce et al. The Lancet profile →
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)

2023 79 citations Eric F. Morand, Edward M Vital et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maria Silk United States	10	576	376	218	197	117	18	884
Hiroko Kanda Japan	18	273 0.5×	300 0.8×	95 0.4×	55 0.3×	130 1.1×	55	823
Arno W. R. van Kuijk Netherlands	15	661 1.1×	562 1.5×	85 0.4×	56 0.3×	114 1.0×	29	1.1k
Nobuo Negoro Japan	13	383 0.7×	414 1.1×	66 0.3×	155 0.8×	118 1.0×	37	756
Bozena Möller Sweden	9	678 1.2×	471 1.3×	203 0.9×	69 0.4×	93 0.8×	12	962
Y. H. Rho South Korea	9	300 0.5×	299 0.8×	82 0.4×	39 0.2×	167 1.4×	11	663
Masafumi Sugiyama Japan	16	362 0.6×	336 0.9×	87 0.4×	33 0.2×	324 2.8×	47	817
Benoît Manfroi France	9	125 0.2×	358 1.0×	118 0.5×	31 0.2×	134 1.1×	13	575
Irene Cecchi Italy	18	731 1.3×	275 0.7×	49 0.2×	88 0.4×	174 1.5×	83	1.1k
Ping-Min Chen United States	12	155 0.3×	439 1.2×	243 1.1×	28 0.1×	179 1.5×	18	854
Elizabeth Papalardo United States	13	740 1.3×	322 0.9×	36 0.2×	137 0.7×	101 0.9×	19	944

Countries citing papers authored by Maria Silk

Since Specialization

Citations

This map shows the geographic impact of Maria Silk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Silk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Silk more than expected).

Fields of papers citing papers by Maria Silk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Silk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Silk. The network helps show where Maria Silk may publish in the future.

Co-authorship network of co-authors of Maria Silk

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Silk. A scholar is included among the top collaborators of Maria Silk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Silk. Maria Silk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Alexis, Andrew, Jill Waibel, Paul F. Wallace, et al.. (2025). Lebrikizumab Improves Atopic Dermatitis in Adult and Adolescent Patients With Skin of Color: 16-Week Results From the ADmirable Study. SKIN The Journal of Cutaneous Medicine. 9(1). s515–s515.

Alexis, Andrew, Jill Waibel, Paul F. Wallace, et al.. (2025). Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable Study. American Journal of Clinical Dermatology. 26(5). 803–817. 1 indexed citations

Yosipovitch, Gil, Lindsay Ackerman, Jerry Bagel, et al.. (2025). 59618 Lebrikizumab improves itch, itch interference on sleep and skin pain in patients with moderate-to-severe atopic dermatitis previously treated with dupilumab. Journal of the American Academy of Dermatology. 93(3). AB61–AB61.

Alexis, Andrew, Jill Waibel, Paul F. Wallace, et al.. (2024). 726 - Interim results from ADmirable, a phase 3b open-label study assessing lebrikizumab in patients with skin of color and moderate-to-severe atopic dermatitis. British Journal of Dermatology. 191(Supplement_2).

Morand, Eric F., Josef S Smolen, Michelle Petri, et al.. (2023). Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis. RMD Open. 9(3). e003302–e003302. 5 indexed citations

Petri, Michelle, Ian N Bruce, Thomas Dörner, et al.. (2023). Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). The Lancet. 401(10381). 1011–1019. 89 indexed citations breakdown →

Morand, Eric F., Edward M Vital, Michelle Petri, et al.. (2023). Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). The Lancet. 401(10381). 1001–1010. 79 indexed citations breakdown →

Dörner, Thomas, Ronald van Vollenhoven, Andrea Doria, et al.. (2022). Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. Arthritis Research & Therapy. 24(1). 112–112. 32 indexed citations

Dörner, Thomas, Yoshiya Tanaka, Ernst R. Dow, et al.. (2022). Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Annals of the Rheumatic Diseases. 81(9). 1267–1272. 32 indexed citations

10.

Birt, Julie, Paul Swinburn, Natalia Bello, et al.. (2021). Patient Experiences, Satisfaction, and Expectations with Current Systemic Lupus Erythematosus Treatment: Results of the SLE-UPDATE Survey. Rheumatology and Therapy. 8(3). 1189–1205. 10 indexed citations

11.

Dörner, Thomas, Yoshiya Tanaka, Michelle Petri, et al.. (2020). Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Science & Medicine. 7(1). e000424–e000424. 43 indexed citations

12.

Silk, Maria, Daniel J. Wallace, Richard Furie, et al.. (2019). 199 Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study. Abstracts. A149.1–A149. 2 indexed citations

13.

Dörner, Thomas, Yoshiya Tanaka, Michelle Petri, et al.. (2019). 185 Baricitinib-associated changes in type I interferon gene signature during a 24-week phase 2 clinical SLE trial. Abstracts. A141.1–A141. 4 indexed citations

14.

Dörner, Thomas, Yoshiya Tanaka, Michelle Petri, et al.. (2019). THU0212 BARICITINIB-ASSOCIATED CHANGES IN GLOBAL GENE EXPRESSION DURING A 24-WEEK PHASE 2 CLINICAL SLE TRIAL DESCRIBE A MECHANISM OF ACTION THROUGH INHIBITION OF JAK/STAT AND IFN RESPONSIVE GENE EXPRESSION. Annals of the Rheumatic Diseases. 78. 384–385. 1 indexed citations

15.

Wallace, Daniel J., Richard Furie, Yoshiya Tanaka, et al.. (2018). Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. 392(10143). 222–231. 356 indexed citations breakdown →

16.

Silk, Maria, et al.. (2018). Efficacy and Safety of Tabalumab in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study (P3.397). Neurology. 90(15_supplement). 9 indexed citations

17.

Kalunian, Kenneth, Murray B. Urowitz, David Isenberg, et al.. (2017). Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. Lara D. Veeken. 57(1). 125–133. 11 indexed citations

18.

Tuttle, Katherine R., Frank C. Brosius, Sharon G. Adler, et al.. (2017). JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. Nephrology Dialysis Transplantation. 33(11). 1950–1959. 210 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact